

ASX Release

SUDA LTD PROGRESSES BUSINESS DEVELOPMENT ACTIVITIES

PERTH, AUSTRALIA – 25 March 2015: SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that it is making good progress towards its business development objectives. Following the BIO-Europe Spring international partnering conference, which was held 9-11 March 2015 in Paris, France, SUDA has advanced some key ongoing discussions regarding its pipeline of first-in-class oral sprays and has also expanded the number of pharmaceutical companies interested in SUDA's OroMist® drug delivery technology.

SUDA's business development team met with 42 companies at the BIO-Europe Spring event, comprising 25 first-time meetings and 17 ongoing dialogues. The team had productive meetings with several major European pharmaceutical companies that are reviewing SUDA's sublingual spray, ArTiMist™, for treatment of paediatric malaria. These companies have existing franchises in the anti-malaria field and have strong ties with the Medicines for Malaria Venture, World Health Organisation and Bill & Melinda Gates Foundation.

The European conference was also a springboard for SUDA's out-licensing initiative for ZolpiMist®, the Company's novel FDA-registered oral spray of zolpidem for treatment of insomnia. SUDA received worldwide rights to ZolpiMist®, excluding the Americas and South Africa, from Amherst Pharmaceuticals as part of the out-licensing deal for SUDA's anti-emetic, SUD-002 (ondansetron), which was announced on 8 January 2015. At BIO-Europe Spring, SUDA met with 15 pharmaceutical companies that are interested in licensing ZolpiMist® for territories covering pan-Europe, Asia, Japan, Korea and the Middle East.

Following BIO-Europe Spring, the Company has increased the number of pharmaceutical companies that it has interacted with to 149 since commencing its outreach to the industry in March 2014. Active discussions with or without confidentiality agreements (CDAs) are ongoing with over 80 of these companies, up from 65 in February 2015. The number of active discussions under CDA has increased to 15 from 14 in February 2015.

Commenting on SUDA's business development progress, Mr Stephen Carter, Chief Executive Officer of SUDA said: "We have made great progress over the last few weeks and were delighted by the quality of interaction and feedback at the BIO-Europe Spring conference. Our hit rate of successful conversion of initial meeting to active discussions has increased to more than 55%, which illustrates the high level of interest in our OroMist® technology platform and pipeline of oral sprays. We aim to advance our most advanced discussions to deal outcomes at the earliest opportunity to provide further validation of the platform and to accelerate our path to financial sustainability."



Further information:

STEPHEN CARTER

CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR

SUDA LTD

Tel: +61 8 6142 5555

sjcarter@sudaltd.com.au

NOTES TO EDITORS:

About SUDA LTD

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing novel oral spray formulations of existing off-patent pharmaceuticals using its proprietary OroMist® drug delivery technology platform. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist®, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist® has been approved in the USA and SUDA has rights to the product outside of the Americas and South Africa. SUDA's most advanced development-stage product, ArTiMist™, is a novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist™ was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction and pre-procedural anxiety. For more information, visit www.sudaltd.com.au